Centrum Medyczne Pratia Katowice — Clinical Trial Site

9 Registered trials

1 Currently recruiting

Organisation

Centrum Medyczne Pratia Katowice

Location

Katowice, Poland

Identifier

ORG-100041721

Address

Ul. Dabrowki 13, 40-081, Poland

Departments

3015:Cardiology
Centrum Medyczne Pratia Katowice
n/a
NA

Clinical trials at this site (9)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1) Recruiting

2022-500699-76-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-18
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A research study to see how a new weekly insulin, insulin icodec when given along with semaglutide helps in reducing the blood sugar level i… Ended

2022-502717-28-00 Diabetes Type 2 5 2024-01-09
A Phase 2 study (NEPTUNE-17) to evaluate efficacy and safety of GSK3858279 in DPNP. Ended

2022-502313-28-00 Diabetic Peripheral Neuropathic Pain 4 2023-12-14
The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the tr… Ended

2022-500449-26-00 Type 2 diabetes mellitus (T2DM) 6 2023-08-03
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease Ended

2022-502234-70-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-07-14
A clinical study of the V116 vaccine for adults who have an increased risk for invasive pneumococcal disease Ended

2022-502791-22-01 Pneumococcal infection 5 2023-05-17